Home > Insider Trading > Filing (0001179110-14-002577)

Filing Details

Accession Number:: 0001179110-14-002577
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-02-12 15:01:22
Reporting Period:: 2014-02-11

Filing Date:: 2014-02-12
Accepted Time:: 2014-02-12 15:01:22
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1586105	Egalet Corp	EGLT	Pharmaceutical Preparations (2834)	463575334

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1030575	Francois Jean Formela	460 East Swedesford Road Suite 1050 Wayne PA 19087		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-02-11	833,098	$0.00	833,098	No	4	C	Indirect	By Atlas Venture Fund
Common Stock	Acquisiton	2014-02-11	863,754	$0.00	1,696,852	No	4	C	Indirect	By Atlas Venture Fund
Common Stock	Acquisiton	2014-02-11	30,000	$0.00	1,726,852	No	4	X	Indirect	By Atlas Venture Fund
Common Stock	Acquisiton	2014-02-11	298,083	$6.00	2,024,935	No	4	C	Indirect	By Atlas Venture Fund
Common Stock	Acquisiton	2014-02-11	85,620	$6.00	2,110,555	No	4	C	Indirect	By Atlas Venture Fund
Common Stock	Acquisiton	2014-02-11	41,667	$12.00	2,152,222	No	4	P	Indirect	By Atlas Venture Fund

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Atlas Venture Fund
No	4	C	Indirect	By Atlas Venture Fund
No	4	X	Indirect	By Atlas Venture Fund
No	4	C	Indirect	By Atlas Venture Fund
No	4	C	Indirect	By Atlas Venture Fund
No	4	P	Indirect	By Atlas Venture Fund

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2014-02-11	833,098	$0.00	833,098	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-02-11	863,754	$0.00	863,754	$0.00
Common Stock	Warrants	Disposition	2014-02-11	30,000	$0.00	30,000	$0.00
Common Stock	Subordinated Convertible Debt	Disposition	2014-02-11	0	$0.00	298,083	$6.00
Common Stock	Senior Convertible Debt	Disposition	2014-02-11	0	$0.00	85,620	$6.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	X	Indirect
No	4	C	Indirect
No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	308,727	Indirect	By Egalet A/S

Footnotes

The reporting person is Egalet A/S, a corporation. Atlas Venture Fund VII, L.P. ("Atlas Venture Fund") is a 23.9% equityholder of Egalet A/S. Atlas Venture Associates VII, L.P. ("Atlas Venture Associates") is the general partner of Atlas Venture Fund, and Atlas Venture Associates VII, Inc. ("Atlas Venture Inc.") is the general partner of Atlas Venture Associates. Dr. Formela is a director of Atlas Venture Inc. and therefore may be deemed to share the right to direct the voting and dispositive control of shares held by Atlas Venture Fund. Dr. Formela disclaims beneficial ownership of any such securities except to the extent of his proportionate pecuniary interest therein, and this report shall not be deemed an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The reporting person is Atlas Venture Fund. Atlas Venture Associates is the general partner of Atlas Venture Fund, and Atlas Venture Inc. is the general partner of Atlas Venture Associates. Dr. Formela is a director of Atlas Venture Inc. and therefore may be deemed to share the right to direct the voting and dispositive control of shares held by Atlas Venture Fund. Dr. Formela disclaims beneficial ownership of any such securities except to the extent of his proportionate pecuniary interest therein, and this report shall not be deemed an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The Series A-1 Preferred Stock automatically converted into Egalet Corporation common stock on a 1-for-1 basis immediately prior to the consummation of Egalet Corporation's initial public offering.
The Series B Preferred Stock automatically converted into Egalet Corporation common stock on a 1-for-1 basis immediately prior to the consummation of Egalet Corporation's initial public offering.
The warrants were automatically exercised into Egalet Corporation common stock immediately prior to the consummation of the Egalet Corporation's initial public offering on a 1-for-1 basis, pursuant to Atlas Venture Fund's purchase of a specified minimum amount of common stock in such offering.
The subordinated convertible debt automatically converted into Egalet Corporation common stock immediately prior to the consummation of Egalet Corporation's initial public offering, based on a conversion price equal to 50% of the per share price in such offering, which was $12 per share.
The senior convertible debt automatically converted into Egalet Corporation common stock immediately prior to the consummation of Egalet Corporation's initial public offering, based on a conversion price equal to 50% of the per share price in such offering, which was $12 per share.